Cargando…

Systems analysis of intracellular pH vulnerabilities for cancer therapy

A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Persi, Erez, Duran-Frigola, Miquel, Damaghi, Mehdi, Roush, William R., Aloy, Patrick, Cleveland, John L., Gillies, Robert J., Ruppin, Eytan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068141/
https://www.ncbi.nlm.nih.gov/pubmed/30065243
http://dx.doi.org/10.1038/s41467-018-05261-x
_version_ 1783343215376596992
author Persi, Erez
Duran-Frigola, Miquel
Damaghi, Mehdi
Roush, William R.
Aloy, Patrick
Cleveland, John L.
Gillies, Robert J.
Ruppin, Eytan
author_facet Persi, Erez
Duran-Frigola, Miquel
Damaghi, Mehdi
Roush, William R.
Aloy, Patrick
Cleveland, John L.
Gillies, Robert J.
Ruppin, Eytan
author_sort Persi, Erez
collection PubMed
description A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-dependent activity profiles into cell-specific genome-scale metabolic models, we develop a computational methodology that explores how intracellular pH (pHi) can modulate metabolism. We show that in silico, alkaline pHi maximizes cancer cell proliferation coupled to increased glycolysis and adaptation to hypoxia (i.e., the Warburg effect), whereas acidic pHi disables these adaptations and compromises tumor cell growth. We then systematically identify metabolic targets (GAPDH and GPI) with predicted amplified anti-cancer effects at acidic pHi, forming a novel therapeutic strategy. Experimental testing of this strategy in breast cancer cells reveals that it is particularly effective against aggressive phenotypes. Hence, this study suggests essential roles of pHi in cancer metabolism and provides a conceptual and computational framework for exploring pHi roles in other biomedical domains.
format Online
Article
Text
id pubmed-6068141
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60681412018-08-02 Systems analysis of intracellular pH vulnerabilities for cancer therapy Persi, Erez Duran-Frigola, Miquel Damaghi, Mehdi Roush, William R. Aloy, Patrick Cleveland, John L. Gillies, Robert J. Ruppin, Eytan Nat Commun Article A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-dependent activity profiles into cell-specific genome-scale metabolic models, we develop a computational methodology that explores how intracellular pH (pHi) can modulate metabolism. We show that in silico, alkaline pHi maximizes cancer cell proliferation coupled to increased glycolysis and adaptation to hypoxia (i.e., the Warburg effect), whereas acidic pHi disables these adaptations and compromises tumor cell growth. We then systematically identify metabolic targets (GAPDH and GPI) with predicted amplified anti-cancer effects at acidic pHi, forming a novel therapeutic strategy. Experimental testing of this strategy in breast cancer cells reveals that it is particularly effective against aggressive phenotypes. Hence, this study suggests essential roles of pHi in cancer metabolism and provides a conceptual and computational framework for exploring pHi roles in other biomedical domains. Nature Publishing Group UK 2018-07-31 /pmc/articles/PMC6068141/ /pubmed/30065243 http://dx.doi.org/10.1038/s41467-018-05261-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Persi, Erez
Duran-Frigola, Miquel
Damaghi, Mehdi
Roush, William R.
Aloy, Patrick
Cleveland, John L.
Gillies, Robert J.
Ruppin, Eytan
Systems analysis of intracellular pH vulnerabilities for cancer therapy
title Systems analysis of intracellular pH vulnerabilities for cancer therapy
title_full Systems analysis of intracellular pH vulnerabilities for cancer therapy
title_fullStr Systems analysis of intracellular pH vulnerabilities for cancer therapy
title_full_unstemmed Systems analysis of intracellular pH vulnerabilities for cancer therapy
title_short Systems analysis of intracellular pH vulnerabilities for cancer therapy
title_sort systems analysis of intracellular ph vulnerabilities for cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068141/
https://www.ncbi.nlm.nih.gov/pubmed/30065243
http://dx.doi.org/10.1038/s41467-018-05261-x
work_keys_str_mv AT persierez systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT duranfrigolamiquel systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT damaghimehdi systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT roushwilliamr systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT aloypatrick systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT clevelandjohnl systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT gilliesrobertj systemsanalysisofintracellularphvulnerabilitiesforcancertherapy
AT ruppineytan systemsanalysisofintracellularphvulnerabilitiesforcancertherapy